Clinical Trials Directory

A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)

This randomized phase III trial studies cytarabine and daunorubicin hydrochloride or idarubicin and cytarabine with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, daunorubicin hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • drug : cytarabine
  • drug : daunorubicin hydrochloride
  • drug : vorinostat
  • drug : Idarubicin
  • other : laboratory biomarker analysis
  • procedure : allogeneic hematopoietic stem cell transplantation

Phase: Phase 3


Ages Eligible For Study:

18 Years - 60 Years

External Links

Explore related trials

Contact information

Primary Contact:

Joselene Sipin-Sayno 650-736-8113

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: